

FOR IMMEDIATE RELEASE

CordLife Opens Medan Representative Office to Meet Growing Demands

- CordLife opens representative office in Medan to better serve the growing number of families who want to bank their babies' cord blood.
- The first and only licensed facility in the country, PT CordLife Indonesia is the fastest growing subsidiary in the group with strong growth in client enrollment last year.
- CordLife's representative office in Medan is recognised and supported by Public Health Service of Medan (Dinas Kesehatan Kota Medan or DinKes Medan) and Indonesia Doctor Association Medan Branch (Ikatan Dokter Indonesia cabang Medan or IDI Medan).

MEDAN, 14th January, 2009 – In its effort to provide a wider network of direct market support and education to generate general awareness for umbilical cord blood banking and therapies in Indonesia, CordLife Ltd., a leading network of private cord blood banks in Asia Pacific (ASX:CBB), announced the official launch of their first representative office in Medan at a press conference graced by Dr Umar Zein, DTM&H, Sp.PD.KPTI, Head of Public Health Service of Medan today.

Headquartered in Jakarta, PT CordLife Indonesia is the fastest growing subsidiary within the group – achieving the strongest client enrollment last year compared to its other facilities in Singapore, Australia, Hong Kong and India. As the only licensed cord blood bank in Indonesia, the opening of their representative office in Medan helps to meet the ever-growing demand for the service and to ensure accurate educational support for the therapy.

“As part of our company philosophy in international quality and continuous support to educate the markets that we serve responsibly, our latest Medan representative office is not only a centre to facilitate the understanding of the exciting field of adult stem cell therapies, but also an opportunity for the company to support the local economy through job creation and offering alternative options for healthcare. Currently, the company also has representation in cities such as Surabaya, and plans are underway to open more offices in major cities as part of our market extension strategy,” said Mr Steven Fang, Group CEO, CordLife Ltd.

Parents in Indonesia are hopeful of what cord blood stem cells can do for their family. Today, these cells are used to treat over 80 diseases; including certain cancers such as leukaemia and breast cancer, blood disorders like Thalassaemia Major and other immunodeficiencies. A boy with leukaemia was saved after receiving his sibling's cord blood stem cells which were collected and processed by CordLife Singapore. The future is promising as researchers worldwide continue to unlock the potential of stem cells, especially in the field of regenerative medicine.

“Cord blood banking has not only become popular but is now a necessary part of a newborn's healthcare need in Indonesia, as more parents get to know about its benefits. It is a small investment today that could go a very long way to ensure the health and the future wellbeing of the child. We are very pleased that parents are banking with CordLife because of our proven track record and strong investments in quality which ensures the cells are ready for use anywhere in the world. Kalbe Farma and CordLife are both internationally reputed and financially strong companies. We are proud to be in partnership with the support of DEPKES (Departemen Kesehatan or Ministry of Health), DINKES, IDI, to bring this important service to Indonesian families” said Mr Djohan Sie, President Director of PT CordLife Indonesia as well as spokesperson of Kalbe Farma, co-owner of PT CordLife Indonesia.

Medan is the third largest city in Indonesia, with approximately 2.5 million residents. Prior to the Medan representative office opening, CordLife's India facility the largest and most advanced in the group - was also officially launched in Kolkata on 13 January 2009.

###

**About PT CordLife Indonesia**

PT CordLife Indonesia remains the only licensed private cord blood banking facility in Indonesia with comprehensive processing and storage capabilities. A joint venture between CordLife Ltd and PT Kalbe Farma Tbk, the technologically advanced facility which can store up to 30,000 cord blood units, is owned and operated by CordLife Indonesia. Headquartered in Jakarta, the facility is built according to the CordLife group's globally accredited quality standards, complete with uninterrupted power, 24-hour security as well as flood and fireproof. For more information, please visit www.cordlife.com.

About CordLife Group

CordLife is a regional cord blood bank that operates the world's largest network of cord blood banks with full processing and cryopreservation storage facilities in Australia, Singapore, Hong Kong, Indonesia and India, as well as marketing offices throughout Asia. The first cord blood bank to be set up in Singapore, and among the first in Asia, CordLife's state of the art facility is the first and only private cord blood bank in Southeast Asia to be accredited by AABB and is also licensed by Singapore's Ministry of Health. CordLife was awarded the prestigious World Economic Forum 'Technology Pioneer' in 2007. CordLife is listed on the Australian Stock Exchange, under the symbol, CBB. For more information, please visit www.cordlife.com.

About PT Kalbe Farma Tbk

Kalbe Farma is the largest publicly listed pharmaceutical company in Southeast Asia, with approximately US\$1.5 billion market capitalisation and US\$600 million in revenue (2005). It promotes and sells its products in 6 major markets in Southeast Asia, which in aggregate represent a population of almost 500 million. Kalbe Farma's revenue is focused on three business segments: consumer health (47%); prescription pharmaceuticals (23%); and distribution and packaging (30%). They have over 12,000 employees, and a sales force of 6,000 covering 80 per cent of the Indonesian consumer health and 100 per cent of the Indonesian prescription pharmaceutical market. For further information, please visit www.kalbefarma.com.

For more information, please contact:

Steven Fang
Group CEO
CordLife Pte Ltd
61 Science Park Road
The Galen #05-16/17/18
Singapore Science Park II
Singapore 117525
Mobile: (65) 9739 8883
Email: sfang@cordlife.com